Home

Biotechs Preparing for the Next Chapter of Growth

PUBLISHED

2022-11-09

Content

Rising interest rates have raised concerns about the ability of biotechs to access capital. Contrary to popular perception, though, the sector is actually quite “healthy”, says portfolio manager Dr Bianca Ogden. Dedicated health funds are stepping in to provide support, while biotechs are refocusing and streamlining their product range, and there has been a flurry of mergers and acquisitions – as the sector prepares for the next chapter of growth.